No Data
Express News | Evenovia Shares Are Trading Higher After the Company Announced It Will Present Results From Its Successful Phase 3 CPN-302 Study of Clobetasol Propionate Suspension 0.05% as a Treatment for Inflammation and Pain Following Ocular Surgery. The Results...
Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo
Express News | Eyenovia Files for Mixed Shelf Offering of up to $100 Mln- SEC Filing
Express News | Eyenovia : Commenced Manufacturing of Registration Batches of Its FDA-Approved Mydriasis Product, Mydcombi
Eyenovia Announces Commencement of Manufacturing of Its Advanced, Second Generation Optejet Device
Eyenovia Announces Share Offering and Warrant Sale for Growth